Skip to main content

CombiMatrix Shares Rise on News of Influenza Dx Service

NEW YORK, Dec. 6 (GenomeWeb News) - Shares in CombiMatrix were up $.07, or 4 percent, at $1.90 in mid-day trading after the company said it plans to offer a DNA-based microarray service to identify types of influenza.

 

The array will enable researchers to genetically identify influenza types, including the H5N1 bird flu. The company said the test can be run on both animal and human samples.

 

CombiMatrix Molecular Diagnostics, a wholly owned subsidiary of CombiMatrix formed in May, will offer the analysis for research purposes because the array is not an FDA approved product.

 

The Influenza microarray, part of CombiMatrix's CatalogArray product line, can detect and accurately type flu strains such as the H5N1 bird flu, as well as provide information on mutations and novel strains of flu not yet seen, the company said.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.